Treatment of early Parkinson's disease: Part 1

European Neurology

Volumn 61, Issue 4, 2009, Pages 193-205

  Simuni, Tanya ^a,g   Lyons, Kelly E ^c   Pahwa, Rajesh ^c   Hauser, Robert A ^d   Comella, Cynthia ^b   Elmer, Lawrence ^e   Weintraub, Daniel ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e MEDICAL COLLEGE OF OHIO   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Dopamine agonists; Levodopa; Monoamine oxidase B inhibitors; Parkinson's disease

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOCOPHEROL;

ASTHENIA; BRADYKINESIA; CLINICAL RESEARCH; CLINICAL TRIAL; CONFUSION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; FRACTURE; HALLUCINATION; HUMAN; HYPOTENSION; INFECTION; INSOMNIA; LEG PAIN; MOTOR ACTIVITY; MUSCLE HYPERTONIA; NAUSEA; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RIGIDITY; SKIN MANIFESTATION; SOMNOLENCE; SYMPTOM; SYNCOPE; TREMOR; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VOMITING; XEROSTOMIA;

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DOPAMINE AGONISTS; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; MOVEMENT DISORDERS; PARKINSON DISEASE; PATIENT COMPLIANCE;

EID: 58749102626     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000197103     Document Type: Review

References (55)

1. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ: Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-982.
2. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ: Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968-975.
3. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ: Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995.
4. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE: Practice Parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
5. Goetz CG, Poewe W, Rascol O, Sampaio C: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
6. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, Lewitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, Lapelle N; for the Movement Disorder Society UPDRS Revision Task Force: Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
7. The Parkinson Study Group: Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
8. The Parkinson Study Group: Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
9. The Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
10. Shannon KM, Bennett JP Jr, Friedman JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997;49:724-728.
11. The Parkinson Study Group: Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997;278:125-130.
12. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF: Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997;49:393-399.
13. Requip® (ropinirole hydrochloride): US Prescribing Information. Research Triangle Park, GlaxoSmithKline, 2006.
14. Brooks DJ, Abbott RJ, Lees AJ, Martignoni E, Philcox DV, Rascol O, Roos RA, Sagar HJ: A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998;21:101-107.
15. The Parkinson Study Group: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-1728.
16. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-276.
17. Neupro® (Rotigotine Transdermal System): US Prescribing Information. Mequon, Schwarz Pharma, 2007.
18. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators: Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-2404.
19. Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):S1-S88.
20. The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
21. Azilect® (rasagiline): US Prescribing Information. Kansas City, Teva Neuroscience, 2006.
22. Selegiline hydrochloride: US Prescribing Information. Toronto, Apotex, 2003.
23. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38.
24. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
25. Mirapex® (pramipexole dihydrochloride): US Prescribing Information. Ingelheim, Boehringer, 2006.
26. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators: Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008;24:2883-2895.
27. Neupro®: Product Information (EMEA). Schwarz Pharma, 2007.
28. Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J: Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET Study. Mov Disord 2006;21:343-353.
29. The Parkinson Study Group: Pramipexole vs. levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
30. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
31. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A: Pramipexole vs. levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
32. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M: Development of dyskinesias in a 5-year trial of ropinirole and L -dopa. Mov Disord 2006;21:1844-1850.
33. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE: Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-2417.
34. Giladi N, Tolosa E, Boothman B, Grosset D, Poewe W, Boroojerdi B, Sommerville KW: Rotigotine transdermal system in patients with idiopathic Parkinson's disease: results of two placebo- and comparator-controlled trials. Poster World Parkinson Congr, Washington, 22-26 February 2006.
35. Etminan M, Gill S, Samii A: Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003;26:439-444.
36. Sethi KD, O'Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, Bertoni JM, Hauser RA: Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Arch Neurol 1998;55:1211-1216.
37. Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C, Ranhosky A, Korts D, Elvin A: Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
38. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL: Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115.
39. Mirapex (pramipexole dihydrochloride) tablets: New Drug Application submitted to the US Food and Drug Administration. http://www.fda.gov/cder/foi/ nda/98/020667. htm. Accessed June 25, 2007.
40. Watts RL, Tagliati M, Patton JM, Poewe W, Boroojerdi B: Safety and tolerability of transdermal rotigotine in early-stage Parkinson's disease. Poster 20th Ann Symp Etiol Pathog Treat Parkinson Dis Other Mov Dis. Chicago, 8 October, 2006.
41. Urquhart J, De Klerk E: Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med 1998;17:251-267, discussion 387-259.
42. Leopold NA, Polansky M, Hurka MR: Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-517.
43. Grosset KA, Bone I, Grosset DG: Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-1507.
44. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
45. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL: Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002;24:302-316.
46. Richter A, Anton SE, Koch P, Dennett SL: The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-2335, discussion 2306.
47. Grosset K, Needleman F, Macphee G, Grosset D: Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004;19:1370-1374.
48. Gimenez-Roldan S, Esteban EM, Mateo D: Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol 2001;24:346-351.
49. Hanna PA, Ratkos L, Ondo WG, Jankovic J: Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm 2001;108:63-70.
50. Goetz CG, Blasucci L, Stebbins GT: Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology 1999;52:1227-1229.
51. Thobois S: Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther 2006;28:1-12.
52. LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J: Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007;30:256-265.
53. Linazasoro G: Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. Clin Neuropharmacol 2008;31:19-24.
54. Linazasoro G: Conversion from dopamine agonists to pramipexole: an open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 2004;251:335-339.
55. Chen JJ: Optimizing use of a dopamine agonist in Parkinson's disease. Pharmacy Times 2007;111-119.